bristol myers cobenfy news - Search News

Bristol Myers Squibb Stock Rises

Cobenfy Approval Brings 20% Upside To Bristol Myers Squibb Stock

This is a big approval for the company, given that Cobenfy doesn’t have the classic side effects seen in other antipsychotic drugs.

Seeking Alpha · 15h

Bristol-Myers Squibb: Unlocking Value With KarXT FDA Approval And Oncology Pipeline Progress

Bristol-Myers Squibb received FDA's approval for Cobenfy, which is poised to be a game changer in the treatment of Schizophrenia. See why BMY stock is a Buy.

CNBC on MSN · 5h

Bristol Myers Squibb stock rises following FDA approval of its schizophrenia drug

CNBC's Angelica Peebles joins 'Fast Money' to report on Bristol Myers Squibb's stock rise following FDA approval of Cobenfy for treating schizophrenia in adults.

8h

Absence of Black Box Warning For Bristol Myers' Schizophrenia Treatment Could Enhance Alzheimer's Psychosis Potential

Cobenfy (xanomeline and trospium chloride, KarXT), an oral medication for schizophrenia in adults. BMO Capital analyst notes ...

17h

Wall Street Breakfast Podcast: Bristol-Myers Wins FDA Nod For Novel Antipsychotic

Bristol-Myers wins FDA nod for novel antipsychotic. DirecTV, Dish close in on merger to form largest US pay-TV service: ...

13hon MSN

Bristol Myers Squibb Stock Rises After Schizophrenia Drug Gets FDA Approval

Key Takeaways Bristol Myers Squibb's drug to treat schizophrenia was approved for use by the Food and Drug Administration.The ...

6hon MSN

These Stocks Are Moving the Most Today: Bristol Myers, Costco, EchoStar, Cassava, Wynn, HP Inc., Acadia Healthcare, and More

Stocks traded mixed Friday after the Federal Reserve’s preferred inflation measure showed that consumer prices continue to ...

Results that may be inaccessible to you are currently showing.

Hide inaccessible results